Poly Medicure Limited · NSE:POLYMED
Poly Medicure — Q4 FY2025 Earnings Presentation
19 slides from Poly Medicure's earnings presentation, May 6, 2025
Slide 1: Submission of Investor's Presentation to stock exchanges
Poly Medicure Limited Regd. Office: 232 B, 3rd Floor, Okhla lnd.ustrial Estate, Phase-Ill, New Delhi· 110 020 (INDIA) :» [POLYMED T: +91 - 11 - 33550700, 47317000 E: [email protected] W: polymed icure.com CIN : L40300DL1995PLC066923 Date: 06U1 May, 2025 Scrip Code: - 531768 Scrip Code:- POLYMED
Slide 2: Investor Presentation – Q4 and FY 25 Results
Investor Presentation – Q4 and FY 25 Results 06th May 2025
Slide 3: Disclaimer
Disclaimer This presentation has been prepared by Poly Medicure Limited (the "Company"), content of which was compiled from sources believed to be reliable for informational purposes only and are based on information regarding the Company and the economic, regulatory, market and other conditions as
Slide 4: Agenda
Agenda Agenda Slide # Polymed Overview and Way Forward 5-8 YoY Performance Summary Q4 and FY25 10 - 11 Key Updates 12 Consolidated and Standalone Financial Performance Summary 13 - 14 Sales Performance Analysis 15-16 Return Ratios Basis Standalone Financials 17
Slide 5: Polymed Overview and Way Forward
Agenda Polymed Overview and Way Forward
Slide 6: Polymed Key Differentiators
Polymed Key Differentiators ▪ Legacy – Operating since 1997 ▪ Leadership – Second fastest growing Medtech Company in India in terms of revenue (Source: Company Filings) ▪ Focus on innovation : Granted 334 patents in India and globally ▪ Manufacturing powerhouse – Backward integrated manufacturing fa
Slide 7: Polymed at a Glance
Polymed at a Glance 12 12 Manufacturing Plants Specialities Across 4 countries 125+ Countries 200+ Medical Devices 3000+ Employee Base 510+ Sales Associates 334 Patents Granted 900+ 1.8 Billion+ Devices Manufacturing Capacity Distributors across India & Globally Per year 6
Slide 8: Navigating the Path
Navigating the Path Building Tomorrow’s Healthcare Solutions Started In 2028 1997 2002-09 2011-19 2020-24 2025 - 27 & beyond Commencement Product and facility New R&D Center, of Manufacturing expansion Acq of Plan 1 Health, Operation New Manufacturing › Launched › Prioritize the › Through a Plants d
Slide 9: Way Forward
Way Forward Research & Development ▪ Targeted R&D investments towards transformative therapeutic areas, aiming towards innovations Emphasizing Inorganic Growth ▪ Integration of AI and IoT technologies to enhance efficiency & precision Strategic Alliances to foster synergies and expanding market reac
Slide 10: Q4 and FY2025 Financial Performance Summary
Agenda Q4 and FY2025 Financial Performance Summary
Slide 11: YoY Performance Summary Q4 FY 25
YoY Performance Summary Q4 FY 25 Figs in Rs. Crs unless specified Consolidated Consolidated Consolidated Consolidated RoCE (1) Revenue EBITDA EBITDA % PAT 440.8 119.5 27.1% 91.8 16.6% 23.8% 34.3% 23.4% 160BPS 378.1 96.5 25.5% 68.4 # of Devices Sold (3) Growth in Top 5 # of Patents Increase in Sales
Slide 12: YoY Performance Summary FY 25
YoY Performance Summary FY 25 Figs in Rs. Crs unless specified Consolidated Consolidated Consolidated Consolidated RoCE (1) Revenue EBITDA EBITDA % PAT 1669.8 452.8 27.1% 338.6 26.6% 23.4% 21.4% 113BPS 31.1% 1375.8 357.7 26.0% 258.3 # of Devices Sold (3) Growth in Top 5 # Patents Increase in Sales N
Slide 13: Key Updates
Key Updates • Commercially launched Drug eluting stent; implanted in 100+ patients with positive feedback on performance Key • Consolidated Q4 and FY revenue growth 16.6% and 21.4% resp. ; Standalone Q4 and FY25 revenue growth of 16.6% and 22.5% resp. Operational • FY25 standalone domestic and expor
Slide 14: Consolidated Financial Performance Summary
Consolidated Financial Performance Summary Figs in Rs. Crs unless specified Particulars Q4 FY 25 Q4 FY 24 Growth % FY 25 FY 24 Growth % Revenue from Operations 440.8 378.1 16.6% 1,669.8 1,375.8 21.4% Cost of Good Sold 147.4 131.2 12.3% 554.7 482.6 14.9% Gross Profit 293.4 246.9 18.9% 1,115.1 893.2 2
Slide 15: Standalone Financial Performance Summary
Standalone Financial Performance Summary Figs in Rs. Crs unless specified Particulars Q4 FY 25 Q4 FY 24 Growth % FY 25 FY 24 Growth % Revenue from Operations 421.0 360.9 16.6% 1,601.8 1,307.2 22.5% Cost of Good Sold 143.9 124.1 16.0% 531.8 452.8 17.4% Gross Profit 277.1 236.9 17.0% 1,070.0 854.4 25.
Slide 16: Standalone Sales Financial Performance Analysis
Standalone Sales Financial Performance Analysis Figs in Rs. Crs unless specified Particulars Q4 FY 25 Q4 FY 24 Growth % FY 25 FY 24 Growth % Domestic Revenue 135.0 108.8 24.1% 486.4 410.0 18.6% Exports Revenue 283.1 249.5 13.5% 1,102.9 889.4 24.0% Other Operating Revenue 2.8 2.7 3.9% 12.6 7.9 59.8%
Slide 17: Segment Wise Sales Performance Analysis
Segment Wise Sales Performance Analysis Figs in Rs. Crs unless specified Particulars Q4 FY 25 Q4 FY 24 Growth % FY 25 FY 24 Growth % Infusion Therapy 252.8 233.3 8.3% 1013.6 860.4 17.8% Renal 46.6 27.6 69.1% 151.3 94.5 60.1% Others 121.5 100.0 21.5% 436.9 352.4 24.0% Total Operating Revenue 421.0 36
Slide 18: Return Ratios Basis Standalone Financials
Return Ratios Basis Standalone Financials ROCE ROE 25.0% 23.0% 23.4% 20.0% 18.7% 18.3% 18.0% 20.0% 18.9% 16.0% 15.5% 17.4% 14.4% 14.0% 15.0% 12.0% 10.0% 10.0% 8.0% 6.0% 5.0% 4.0% 2.0% 0.0% 0.0% FY 22 FY 23 FY 24 FY 25 FY 22 FY 23 FY 24 FY 25 *Excludes the amount raised through QIP in August 2024, EB
Slide 19: Thank You
Thank You For any investor related queries reach us at: [email protected]